# Bluejay Diagnostics (BJDX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BJDX
## Company Profile
- Ticker: BJDX
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics
## Stock Data
- Close: 1.03 USD
- Market cap: 4490663.1 USD
- Last updated: 2026-09-08
## Business Overview
### Critical-Care Diagnostics
Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform.
### Symphony Platform
Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow.
### Symphony IL-6 Test
The lead test measures interleukin-6 as an aid in assessing critically ill patients. The SYMON-II pivotal study enrolled hospitalized patients to support analytical and clinical validation.
### U.S. Manufacturing Strategy
Bluejay is establishing domestic manufacturing and supply-chain capacity in preparation for regulatory submission and potential commercialization.
## Why The Stock Is Moving

Following the latest company update, “Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets”, BJDX closed up 23.7% at $1.03 on Sep 8, 2026. The move occurred in the trading session associated with this partnership update.

## Future Catalysts

- Planned FDA 510(k) submission for the Symphony IL-6 test following completion of analytical and clinical validation.

## Recent News
- 2026-09-08 10:30 EST — [Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-and-lovell-government-services-announce-partnership-to-expan-5435714e) — Source: Bluejay Diagnostics
- 2026-08-13 10:00 EST — [Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-reports-q2-2026-results-strengthened-balance-sheet-supports--24365077) — Source: Bluejay Diagnostics
- 2026-07-21 10:30 EST — [Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-successful-completion-of-enrollment-in-the-symon-i-f7cec8c0) — Source: Bluejay Diagnostics
- 2026-06-06 00:13 EST — [Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-closing-of-up-to-23-7-million-private-placement-pr-08b77eb3) — Source: Bluejay Diagnostics
- 2026-06-02 16:19 EST — [Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-up-to-23-6-million-private-placement-priced-at-the-market-under-nasdaq-rules) — Source: Bluejay Diagnostics